Share on Facebook
Share on Twitter
Share on LinkedIn

WASHINGTON (Reuters) – Pharmaceutical companies Genentech and OSI Pharmaceuticals LLC will pay $67 million to resolve allegations they made misleading statements about the effectiveness of lung cancer drug Tarceva, the U.S. Justice Department said on Monday.

The claims alleged that between 2006 and 2011, the companies misrepresented the effectiveness of Tarceva to physicians and other healthcare providers to treat certain patients with non-small cell lung cancer, the department said in a statement.

Read More